Cargando…

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()

OBJECTIVES: To determine the prevalence of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r. SUBJECTS AND METHODS: Cross-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brandariz-Nuñez, David, Correas-Sanahuja, Marcelo, Guarc, Eva, Picón, Rafael, García, Bárbara, Gil, Rocío
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486822/ https://www.ncbi.nlm.nih.gov/pubmed/32953990 http://dx.doi.org/10.1016/j.medcle.2020.06.012

Ejemplares similares

Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Apixaban/lopinavir/ritonavir interaction: An increase in drug level leading to high antifactory-Xa activity following drug-drug interaction: case report
Publicado: (2021)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Ye, Linhu, et al.
Publicado: (2021)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
Publicado: (2020)

Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19
por: Skalafouris, Christian, et al.
Publicado: (2023)

Hydroxychloroquine/lopinavir/ritonavir/tacrolimus interaction: Increased tacrolimus level secondary to pharmacokinetic drug interaction and off label use: case report
Publicado: (2021)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes
por: Grossman, Zehava, et al.
Publicado: (2014)

Immunosuppressants/Lopinavir/ritonavir: Elevated drug level, Covid 19 and reactivation of Herpes Zoster: 2 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Publicado: (2022)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Lopinavir/ritonavir/sirolimus interaction: Hepatitis following an off-label use: case report
Publicado: (2022)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Lopinavir/ritonavir/sotalol: Various toxicities: 9 case reports
Publicado: (2021)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
por: Purwati,, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3eif8c4nt6rv1iguktlne7m46q